-+ 0.00%
-+ 0.00%
-+ 0.00%

Hyloris Developments Presents Drug Pipeline and Commercial Growth Strategy

PUBT·11/16/2026 18:25:46
Listen to the news
Hyloris Developments Presents Drug Pipeline and Commercial Growth Strategy
  • Hyloris Developments outlined clinical advances and portfolio cuts at the Jefferies Global Healthcare Conference in London.
  • HY-094 secured Phase 3 IND clearance; estimated development costs for Hyloris remain below EUR 7 million.
  • Four products are commercialized, with initial royalties and profit sharing from Tranexamic Acid IV RTU.
  • Rosemont filed an NDA for atomoxetine oral liquid; submissions are planned for dofetilide IV and aspirin IV.
  • Three programs were discontinued, including XTRAZA’s US Phase 3 program, as investment shifts toward programs with the strongest potential.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyloris Developments SA published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.